Related references
Note: Only part of the references are listed.Design, synthesis, and studies of small molecule STAT3 inhibitors
Deepak Bhasin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects
Khandaker A. Z. Siddiquee et al.
ACS CHEMICAL BIOLOGY (2007)
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
A. Pardanani et al.
LEUKEMIA (2007)
Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis
Dae Joon Kim et al.
MOLECULAR CARCINOGENESIS (2007)
Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer
L. Tam et al.
BRITISH JOURNAL OF CANCER (2007)
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity
Khandaker Siddiquee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Expression of anaplastic lymphoma kinase, tyrosine-phosphorylated STAT3, and associated factors in pediatric anaplastic large cell lymphoma - A report from the children's oncology group
Michel R. Nasr et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2007)
Constitutive and induced activation of JAK/Stat pathway in leukemogenic and asymptomatic human T-cell lymphoptropic virus type 1 (HTLV-1) transformed rabbit cell lines
Angela Samaan et al.
IMMUNOLOGY LETTERS (2007)
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo
A. Iwamaru et al.
ONCOGENE (2007)
Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma
Liqing Zhuang et al.
MODERN PATHOLOGY (2007)
Stat3 activation in human endometrial and cervical cancers
C-L Chen et al.
BRITISH JOURNAL OF CANCER (2007)
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer
Marjan Berishaj et al.
BREAST CANCER RESEARCH (2007)
The STAT3 oncogene as a predictive marker of drug resistance
Benjamin Barre et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Stattic: A small-molecule inhibitor of STAT3 activation and dimerization
Jochen Schust et al.
CHEMISTRY & BIOLOGY (2006)
Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation
Kwang Woon Kim et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer
Zhenfeng Duan et al.
CLINICAL CANCER RESEARCH (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
BCR-ABL activates STAT3 via JAK and MEK pathways in human cells
Paul Coppo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival
Lanxi Song et al.
CANCER RESEARCH (2006)
被撤回的出版物: Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells (Retracted article. See vol. 8, artn no. 1, 2011)
Mariko Tomita et al.
RETROVIROLOGY (2006)
Activation of Stat3 in human melanoma promotes brain metastasis
TX Xie et al.
CANCER RESEARCH (2006)
Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein
A Kotha et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy
YK Lee et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells
T Gritsko et al.
CLINICAL CANCER RESEARCH (2006)
Activation of Stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated Src and survivin expression
N Diaz et al.
CLINICAL CANCER RESEARCH (2006)
STAT3-mediated transcription of Bcl-2, Mcl-1 and c-lAP2 prevents apoptosis in polyamine-depleted cells
S Bhattacharya et al.
BIOCHEMICAL JOURNAL (2005)
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
M Kortylewski et al.
NATURE MEDICINE (2005)
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study
B Burtness et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway
S Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
H Greulich et al.
PLOS MEDICINE (2005)
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells
S Nam et al.
CANCER RESEARCH (2005)
Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines - Inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells
Q Lin et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells
J Turkson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo
LF Gao et al.
CLINICAL CANCER RESEARCH (2005)
Role of Stat3 in regulating p53 expression and function
GL Niu et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
Q Xu et al.
ONCOGENE (2005)
The role of cetuximab in the treatment of squamous cell cancer of the head and neck
B Burtness
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
Regulation of gene-activation pathways by pias proteins in the immune system
K Shuai et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors
T Kusaba et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3
K Schlessinger et al.
CANCER RESEARCH (2005)
Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1
S Loeffler et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Targeting STAT3 affects melanoma on multiple fronts
M Kortylewski et al.
CANCER AND METASTASIS REVIEWS (2005)
Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer
EB Haura et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complexthat regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas
MJ Gray et al.
ONCOGENE (2005)
Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells
S Nam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells
H Song et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells
L O Flowers et al.
ONCOGENE (2005)
Inhibition of integrin-linked kinase by QLT0254 inhibits Akt-dependent pathways and is growth inhibitory in orthotopic primary pancreatic cancer xenografts
CYF Yau et al.
CANCER RESEARCH (2005)
In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach:: implications for cancer therapy
SC Xi et al.
ONCOGENE (2005)
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer
SW Han et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis
KS Chan et al.
CANCER RESEARCH (2004)
The stats of cancer - New molecular targets come of age
H Yu et al.
NATURE REVIEWS CANCER (2004)
Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells
DR Hodge et al.
CANCER BIOLOGY & THERAPY (2004)
RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells
SO Lee et al.
PROSTATE (2004)
Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells
YS Pu et al.
PROSTATE (2004)
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
TH Wang et al.
NATURE MEDICINE (2004)
STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells
N Kanda et al.
ONCOGENE (2004)
STAT proteins as novel targets for cancer drug discovery
J Turkson
EXPERT OPINION ON THERAPEUTIC TARGETS (2004)
Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy
KS Selander et al.
CANCER RESEARCH (2004)
Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival
R Burger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer
T Toyonaga et al.
CANCER LETTERS (2003)
Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways
CM Leu et al.
ONCOGENE (2003)
Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells
L Konnikova et al.
BMC CANCER (2003)
Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer
A Scholz et al.
GASTROENTEROLOGY (2003)
Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck
SC Xi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells
LX Song et al.
ONCOGENE (2003)
SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia
CY Chen et al.
GENES CHROMOSOMES & CANCER (2003)
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma
O Galm et al.
BLOOD (2003)
Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway
LH Wei et al.
ONCOGENE (2003)
Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells
CY Thomas et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis
DY Wei et al.
ONCOGENE (2003)
Control mechanism of JAK/STAT signal transduction pathway
S Yamada et al.
FEBS LETTERS (2003)
Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells
N Jing et al.
DNA AND CELL BIOLOGY (2003)
Src family kinases: Potential targets for the treatment of human cancer and leukemia
M Warmuth et al.
CURRENT PHARMACEUTICAL DESIGN (2003)
Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells
SO Rahaman et al.
ONCOGENE (2002)
Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas
H Nagai et al.
CANCER LETTERS (2002)
Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells
PJ Real et al.
ONCOGENE (2002)
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
G Niu et al.
ONCOGENE (2002)
Transcription factors as targets for cancer therapy
JE Darnell
NATURE REVIEWS CANCER (2002)
Constitutive activation of Jak/STAT proteins in Epstein-Barr virus-infected B-cell lines from patients with posttransplant lymphoproliferative disorder.
RR Nepomuceno et al.
TRANSPLANTATION (2002)
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
GL Niu et al.
ONCOGENE (2002)
Constitutive activation of Stat3α in brain tumors:: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2)
LK Schaefer et al.
ONCOGENE (2002)
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
A Zamo et al.
ONCOGENE (2002)
Retinoic acid increases proliferation rate of GL-15 glioma cells, involving activation of STAT-3 transcription factor
E Paillaud et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2002)
STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P
A Horiguchi et al.
KIDNEY INTERNATIONAL (2002)
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation
J Turkson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells
WM Burke et al.
ONCOGENE (2001)
Constitutive activation of STAT transcription factors in acute myelogenous leukemia
K Spiekermann et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2001)
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells
R Garcia et al.
ONCOGENE (2001)
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity
H Yoshikawa et al.
NATURE GENETICS (2001)
Constitutive STAT3-activation in Sezary syndrome:: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells
KW Eriksen et al.
LEUKEMIA (2001)
Apoptosis in multiple myeloma: Therapeutic implications
D Chauhan et al.
APOPTOSIS (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts:: Role of activated STAT3 signaling
D Sinibaldi et al.
ONCOGENE (2000)
Modulation of STAT signaling by STAT-interacting proteins
K Shuai
ONCOGENE (2000)
STAT signaling in head and neck cancer
JI Song et al.
ONCOGENE (2000)
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo
JR Grandis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Epidermal growth factor receptor-mediated Stat3 signaling blocks apoptosis in head and neck cancer
JR Grandis et al.
LARYNGOSCOPE (2000)
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts
PW Vincent et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Activation of Stat3 and Stat1 DNA binding and transcriptional activity in human brain tumour cell lines by gp130 cytokines
LK Schaefer et al.
CELLULAR SIGNALLING (2000)